We would love to hear your thoughts about our site and services, please take our survey here.
Ahfam - great research re SDC1802. It’s surprising that the intention to send SDC1802 straight into clinical Cancer trials was not picked up at the half year investormeet. It could be a significant statement which results in clinical trials for 1802 starting sooner than we had thought. Nice find.
‘The phase1a part of the trial is expected to provide safety and dosing information applicable for any future trials in patients with other autoimmune deceases and potentially in patients with the acute respiratory systems of viral infections, should the company decide to progress such trials.’’
We only need success in one indication but a successful completion of safety phase1a dosing and the potential of wider autoimmune and respiratory applicability would surely be an attractive package for pharmas to buy in at this stage. I am expecting Pharma interest when phase 1a is completed.
https://assets.researchsquare.com/files/rs-1990572/v2/f190c381-2a90-497e-b8e7-9d97d5f76ae1.pdf?c=1671032681
Another recent report (Nov 2022) supporting the role of CHK1 inhibitors and Gemcitabane in treating Small Cell Lung Cancer.
If GSK/Sierra are still holding out on SRA 737 clinical data they should be publicly shamed that they are both doing the dirty on what is the biggest Cancer Charity in the World. Time for someone in the press to dig out a good story on the holding back of important data that can help save lives.
So if the 13k sell is an ISA transfer there should be a corresponding buy at near the same price. So ignoring the ISA trade it was Buys 17,391 and sells 14,250 yet there is a price drop os approx 5%.
Par for the course as usual. How they get away with it is beyond me.
Sareum will obviously need to provide clarification asap if this is incorrect.
My only take on it possibly being accurate would be in relation to the company’s plans to participate in Covid and respiratory trials which if successful could be fast tracked?
Does Dr Stephen Parker’s short tweet on the weekend suggest that he was still in San Francisco at least two days after the JP Morgan conference finished? Sorry can’t post a copy as my Twitter Account is down.
Interesting read in the current climate. Note the dangers of not having watertight contract arrangements should a Pharma decide to shelve a Biotech’s asset. CPF’s contract with Sierra for SRA 737 is a classic example of what can go wrong.
https://www.rbccm.com/en/gib/biopharma/episode/biotech-and-big-pharma-blueprint-for-successful-partnership?listen